- Home
- REFI vs OABI Comparison
REFI vs OABI Comparison
Compare REFI & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | OABI |
|---|---|---|
| Founded | 2021 | 2012 |
| Country | United States | United States |
| Employees | N/A | 114 |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 253.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | REFI | OABI |
|---|---|---|
| Price | $12.30 | $1.77 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $20.00 | $6.67 |
| AVG Volume (30 Days) | 123.8K | ★ 258.6K |
| Earning Date | 03-12-2026 | 03-04-2026 |
| Dividend Yield | ★ 15.11% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $48,857,628.00 | N/A |
| Revenue This Year | $19.62 | $52.42 |
| Revenue Next Year | $10.79 | $64.69 |
| P/E Ratio | $7.42 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $11.62 | $1.22 |
| 52 Week High | $15.49 | $2.57 |
Technical Indicators
Market Signals| Indicator | REFI | OABI |
|---|---|---|
| Relative Strength Index (RSI) | 53.71 | 45.49 |
| Support Level | $12.23 | $1.71 |
| Resistance Level | $12.46 | $1.89 |
| Average True Range (ATR) | 0.25 | 0.12 |
| MACD | 0.03 | -0.01 |
| Stochastic Oscillator | 54.83 | 21.62 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.